» Articles » PMID: 36012233

Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Aug 26
PMID 36012233
Authors
Affiliations
Soon will be listed here.
Abstract

Antiphospholipid syndrome (APS) is a hypercoagulable state accompanied by the presence of heterogeneous antiphospholipid antibodies (aPL), which nonspecifically affect hemostasis by the presence of lupus anticoagulans (LA), anticardiolipin antibodies (aCL), antibodies against β2-glycoprotein-I (anti-β2GPI), but also non-criteria antibodies such as antibodies against β2-glycoprotein-I domain I (anti-DI), anti-phosphatidylserine/prothrombin (anti-PS/PT), anti-annexin V, and many others. The main target of the antibodies is the activated protein C (APC) system, the elimination of which can manifest itself as a thrombotic complication. The aim of this study was to determine the thrombogenicity of antibodies using a modified protein C-activated thrombin generation assay (TGA) on a group of 175 samples suspected of APS. TGA was measured with/without APC and the ratio of both measurements was evaluated (as for APC resistance), where a cut-off was calculated ≤4.5 (90th percentile) using 21 patients with heterozygous factor V Leiden mutation (FV Leiden heterozygous). Our study demonstrates the well-known fact that multiple positivity of different aPLs is a more severe risk for thrombosis than single positivity. Of the single antibody positivity, LA antibodies are the most serious (p value < 0.01), followed by aCL and their subgroup anti-DI (p value < 0.05). Non-criteria antibodies anti-annexin V and anti-PT/PS has a similar frequency occurrence of thrombogenicity as LA antibodies but without statistical significance or anti-β2GPI1 positivity. The modified TGA test can help us identify patients in all groups who are also at risk for recurrent thrombotic and pregnancy complications; thus, long-term prophylactic treatment is appropriate. For this reason, it is proving increasingly beneficial to include the determination antibodies in combination with modified TGA test.

Citing Articles

H3K4me3-Mediated FOXJ2/SLAMF8 Axis Aggravates Thrombosis and Inflammation in β2GPI/Anti-β2GPI-Treated Monocytes.

Tan Y, Qiao J, Yang S, Liu H, Wang Q, Liu Q Adv Sci (Weinh). 2024; 11(24):e2309140.

PMID: 38639399 PMC: 11199983. DOI: 10.1002/advs.202309140.


Determining Thrombogenicity: Using a Modified Thrombin Generation Assay to Detect the Level of Thrombotic Event Risk in Lupus Anticoagulant-Positive Patients.

Bradacova P, Slavik L, Ulehlova J, Kriegova E, Jara E, Bultasova L Biomedicines. 2023; 11(12).

PMID: 38137550 PMC: 10741461. DOI: 10.3390/biomedicines11123329.


A Comparative Analysis of Anticardiolipin, Anti-Β2-Glycoprotein-1, and Lupus Anticoagulants in Saudi Women with Recurrent Spontaneous Abortions.

Shaikhomar O, Ali S J Pers Med. 2023; 13(1).

PMID: 36675663 PMC: 9861935. DOI: 10.3390/jpm13010002.

References
1.
Aydin S . A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA. Peptides. 2015; 72:4-15. DOI: 10.1016/j.peptides.2015.04.012. View

2.
Devreese K . How to Interpret Antiphospholipid Laboratory Tests. Curr Rheumatol Rep. 2020; 22(8):38. DOI: 10.1007/s11926-020-00916-5. View

3.
Pierangeli S, Favaloro E, Lakos G, Meroni P, Tincani A, Wong R . Standards and reference materials for the anticardiolipin and anti-β2glycoprotein I assays: a report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies. Clin Chim Acta. 2011; 413(1-2):358-60. DOI: 10.1016/j.cca.2011.09.048. View

4.
Bertolaccini M, Amengual O, Atsumi T, Binder W, de Laat B, Forastiero R . 'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus. 2011; 20(2):191-205. DOI: 10.1177/0961203310397082. View

5.
Conti F, Andreoli L, Crisafulli F, Mancuso S, Truglia S, Tektonidou M . Does seronegative obstetric APS exist? "pro" and "cons". Autoimmun Rev. 2019; 18(12):102407. DOI: 10.1016/j.autrev.2019.102407. View